{
    "nct_id": "NCT04016389",
    "official_title": "FIGO 2018 Stage IB2 (> 2 to ≤4cm) Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa) / Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility",
    "inclusion_criteria": "Part 1 - Eligibility Criteria for Neoadjuvant Chemotherapy\n\n* Patients must have histologically confirmed invasive cervical cancer with adenocarcinoma, adenosquamous or squamous histology and FIGO 2018 IB2 measuring >2 cm - ≤4 cm by radiological imaging (MRI).\n* Patients must be premenopausal and wish to preserve fertility.\n* At time of registration, patient may not have had any prior therapy to treat their cancer lesion.\n* Eastern Cooperative Group (ECOG) performance status ≤ 2.\n* Within 7 days of the proposed start of treatment, patients must have normal organ and marrow function.\n* No evidence of active uncontrolled infection (patients on antibiotics are eligible).\n* Patient must have disease that is measurable per the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\n* Ability to understand and willing to sign a written informed consent document.\n* Patients must agree to use effective contraceptive methods prior to study entry, during study participation, and for at least one year after the fertility-sparing surgery (FSS) procedure. A serum pregnancy test within 72 hours prior to study registration is required.\n\nPart 2 - Eligibility Criteria for Fertility Sparing Surgery (FSS)\n\n* Completed 3 cycles of neo-adjuvant chemotherapy and achieved a complete response (CR) or partial response (PR) with reduction of the lesion to <2 cm on physical examination and MRI.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 40 Years",
    "exclusion_criteria": "Part 1 - Exclusion Criteria for Neoadjuvant Chemotherapy\n\n* Patients who have had chemotherapy or radiotherapy or surgery for their cancer.\n* Patients who are receiving any other investigational agents.\n* Patients with other cancers requiring ongoing treatment.\n* Patients with known / evidence of brain metastases are excluded from participation in this clinical trial.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel, carboplatin, or cisplatin or other agents used in study.\n* Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Patients who are pregnant or breastfeeding\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues.\n\nPart 2 - Exclusion Criteria for Fertility Sparing Surgery\n\n* Patient unable to complete 3 cycles of neoadjuvant chemotherapy\n* Suboptimal response to neoadjuvant chemotherapy according to investigator\n* Residual lesion > 2cm or disease progression while on chemotherapy",
    "miscellaneous_criteria": ""
}